SOLASIA-PHARMA
15.6.2020 09:50:08 CEST | Business Wire | Press release
Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced the positive results from the pivotal Phase 2 study with SP-02 (a new anti-cancer drug, international generic name: darinaparsin, hereinafter “darinaparsin”) for relapsed or refractory peripheral T-cell lymphoma (hereinafter “PTCL”) in Asia.
- The primary endpoint (antitumor effect) was achieved.
- No new safety concerns were identified in the safety analysis.
- This study was conducted as the final registration trial for the indication of relapsed or refractory PTCL. Solasia begins preparing for the NDA Filing.
Darinaparsin is a novel mitochondrial targeting drug (organic arsenic compound) that has been developed for the treatment of various hematological cancers and solid cancers. This study was conducted as a multinational, multicentre, single-arm, open-label, non-randomized study to evaluate the efficacy and safety of darinaparsin monotherapy in relapsed or refractory patients with PTCL in Japan, South Korea, Taiwan and Hong Kong.
Solasia holds an exclusive worldwide license to develop and commercialize darinaparsin. For Japan market, Solasia has already entered into an exclusive license agreement with Meiji Seika Pharma Co., Ltd., for the commercialization of darinaparsin, and for Latin America, with HB Human BioScience SAS. Based on these positive results, Solasia will actively seek licensing partners for the United States, Europe and other regions.
About darinaparsin (SP-02)
Darinaparsin is a novel mitochondrial-targeted agent (organoarsenic) being developed for the treatment of various hematologic and solid cancers. In a US Phase 2 study, darinaparsin demonstrated evidence of clinical activity in lymphoma, in particular PTCL. Furthermore, the Phase 1 study done in US, and the Pan-Asian Phase 1 study both demonstrated positive efficacy and safety. Darinaparsin has been granted orphan drug designation in US and EU.
For more information, please see at https://www.solasia.co.jp/en/pipeline/sp-02.html
About peripheral T-cell lymphoma (PTCL)
Malignant lymphoma is a general term to describe tumors that have developed from lymphocytes, mainly in the immune tissue (lymph nodes). A variety of clinical pathological characterizations present in malignant lymphoma. Malignant lymphoma is classified as Hodgkin Lymphoma (HL) and Non-Hodgkin’s Lymphoma (NHL). NHL mainly consists of B-cell lymphoma and T-cell lymphoma. It is reported that relatively higher incidence of T-cell lymphoma rather than B-cell lymphoma in Japan and Asia. PTCL is a major subtype of T-cell lymphoma with a high incidence rate. Although there is no standard treatment established to treat PTCL, CHOP therapy is widely used as front line treatment. However, there is a large need for more effective and safer therapies as the clinical efficacy of CHOP to treat PTCL is limited. In addition, there are no standard salvage therapies for PTCL, and new, breakthrough therapies are needed.
About Solasia
Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers.
For more information, please visit https://www.solasia.co.jp/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Expands Shopper Experience Platform to Improve Product Discovery in AI-Powered Shopping28.10.2026 12:00:00 CET | Press release
New optimization capabilities and NIQ’s CONTENT Framework help brands strengthen product visibility, relevance and performance across retail and AI-powered shopping channels NielsenIQ (NYSE: NIQ)today announced new optimization capabilities for its Shopper Experience Platform, supported by its CONTENT Framework, a seven-pillar approach to evaluating and improving product content. Together, they enable brands to evaluate product content and imagery against retailer requirements and category expectations, identify gaps, and prioritize improvements that strengthen product discovery across retailer sites, search engines, and AI-powered shopping channels. A product can be accurate, complete, and retailer-compliant yet still be difficult for shoppers to find, understand, or choose. This challenge is growing as AI assistants, retailer algorithms, and recommendation engines play a larger role in shopping. According to NIQ's Consumer Outlook: Guide to 2027, 55% of global consumers report having
Tula Technology Signs Landmark Agreement Licensing Dynamic Motor Drive® to Global Tier 1 Supplier28.10.2026 12:00:00 CET | Press release
Agreement covers supplier’s full E-drive portfolio, creating global production opportunities Tula Technology, Inc., a leader in propulsion efficiency and developer of Dynamic Motor Drive® (DMD), today announced that it has signed an intellectual property license agreement with a global Tier 1 automotive supplier covering the supplier’s entire E-drive portfolio. Under the agreement, the Tier 1 supplier has a non-exclusive license to Tula’s DMD portfolio of patents covering the U.S., Europe, and Asia. The agreement marks the first commercial deployment of DMD spanning the supplier's complete E‑drive portfolio. DMD is an innovative software‑only technology that strategically applies torque pulses under optimal conditions, reducing drive‑cycle energy consumption by 0.5‑2.0%. Because DMD is implemented entirely in software, it requires no hardware changes or additions, allowing suppliers and OEMs to integrate the technology into existing E‑drive systems with minimal engineering effort. The
PayNet Enables Malaysian Mobile Banking App Users to Make Overseas DuitNow QR Payments via Alipay+28.10.2026 11:42:00 CET | Press release
Malaysians can now pay using supported local banking apps in five destinations: Chinese Mainland, Hong Kong SAR, South Korea, the Philippines and Laos. More markets will be added progressively. Payments Network Malaysia Sdn Bhd (PayNet) today announced the launch of outbound DuitNow QR payment connectivity through Alipay+, the unified wallet gateway of Ant International. Malaysians can now use supported local mobile banking apps to pay at participating Alipay+-supported merchants in five destinations: Chinese Mainland, Hong Kong SAR, South Korea, the Philippines and Laos. The initial three launch banks are Maybank, CIMB and Hong Leong Bank, with Bank Islam set to join soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261028063575/en/ From left to right: Michael Guo, General Manager of Alipay+ SEA, ANZ and South Asia, Ant International; Praveen Rajan, Chief Executive Officer of PayNet; Danny Chung, General Manager of Alipa
euroAtlantic Airways Adds Second A330-300, Expanding Widebody Capacity28.10.2026 11:00:00 CET | Press release
euroAtlantic Airways (“EAA”), a Njord Partners portfolio company and a Portuguese ACMI and charter airline, has added a second Airbus A330-300 leased from Jackson Square Aviation (JSA), further expanding its widebody capacity. The second aircraft arrived in Portugal on 28 October 2026, bringing EAA’s total fleet size to eight. The first aircraft, CS-TGI, has already been inducted into EAA’s Air Operator Certificate and is operating commercial flights, including short-term ACMI and charter assignments. The second aircraft, an Airbus A330-300 which will carry the registration CS-TGJ, will now go through induction into EAA’s Air Operator Certificate, subject to the usual regulatory approvals. Both aircraft are leased from JSA and seat 290 passengers across three classes. The addition of the second aircraft strengthens EAA’s ability to serve a diversified range of customer requirements across global markets. In line with its long-term plans, EAA is well positioned for continued disciplined
Blue Matter Acquires Cognite, a Leading Healthcare Communications Agency28.10.2026 11:00:00 CET | Press release
Blue Matter, a world-class consulting firm serving the life sciences industry, today announced the acquisition of Cognite, a leading global healthcare communications agency that helps pharmaceutical and biotech companies bring science to life through an impressive range of scientific, medical, and commercial communications services. Cognite represents a significant step forward in strengthening Blue Matter’s growing range of communications capabilities. “Blue Matter is recognized as a valuable strategic resource and a thought leader when it comes to corporate, portfolio, product, and functional strategy in biopharma,” said Blue Matter CEO Ashwin Dandekar. “Over the past few years, we’ve been systematically bringing together the creative and communications capabilities that are often so crucial to bringing those strategies to life with healthcare providers, patients, payers, investors, and other stakeholders. Cognite’s array of capabilities, creativity, and team culture are a perfect fi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom